Commitments and Contingencies (Details Textual) (USD $)
|
3 Months Ended | 9 Months Ended | 0 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 0 Months Ended | 1 Months Ended | 9 Months Ended | 12 Months Ended | 0 Months Ended | 9 Months Ended | 1 Months Ended | 9 Months Ended | 1 Months Ended | 9 Months Ended | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2014
|
Sep. 30, 2013
|
Sep. 30, 2014
|
Sep. 30, 2013
|
Jun. 20, 2014
|
Dec. 31, 2013
|
Jan. 27, 2014
Manufacturing Agreement [Member]
|
Sep. 30, 2014
Manufacturing Agreement [Member]
|
Sep. 30, 2014
Einstein [Member]
|
Sep. 30, 2014
Abbview Biotherapeutics Corp [Member]
Product Development and Patent License Agreement [Member]
|
Sep. 30, 2014
Abbview Biotherapeutics Corp [Member]
After First Net Sales [Member]
|
Sep. 30, 2014
Abbview Biotherapeutics Corp [Member]
Phase I Clinical Trial of a licensed product [Member]
|
Sep. 30, 2014
Abbott Biotherapeutics Corp [Member]
After First Net Sales [Member]
Product Development and Patent License Agreement [Member]
|
Sep. 30, 2014
Abbott Biotherapeutics Corp [Member]
Phase I Clinical Trial of a licensed product [Member]
|
Sep. 30, 2014
Oak Ridge National Laboratory [Member]
2013 [Member]
|
Sep. 30, 2014
Oak Ridge National Laboratory [Member]
2014 [Member]
|
May 16, 2013
Aptiv Solutions [Member]
|
Oct. 22, 2012
Aptiv Solutions [Member]
|
Aug. 06, 2012
Aptiv Solutions [Member]
|
Dec. 31, 2007
Aptiv Solutions [Member]
|
Sep. 30, 2014
Aptiv Solutions [Member]
|
Dec. 31, 2012
Aptiv Solutions [Member]
|
Jun. 15, 2012
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
|
Sep. 30, 2014
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
|
Sep. 30, 2013
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
|
Sep. 30, 2014
Fred Hutchinson Cancer Research Center [Member]
Clinical Trial Agreement [Member]
|
Dec. 31, 2013
Fred Hutchinson Cancer Research Center [Member]
Clinical Trial Agreement [Member]
|
Jul. 19, 2012
Fred Hutchinson Cancer Research Center [Member]
Clinical Trial Agreement [Member]
|
Jun. 15, 2012
Fred Hutchinson Cancer Research Center [Member]
Maximum [Member]
license and sponsored research agreement [Member]
|
Jun. 15, 2012
Fred Hutchinson Cancer Research Center [Member]
Minimum [Member]
license and sponsored research agreement [Member]
|
Aug. 28, 2012
University of Texas M.D. Anderson Cancer Center [Member]
Clinical Trial Agreement [Member]
patients
|
Sep. 30, 2014
University of Texas M.D. Anderson Cancer Center [Member]
Clinical Trial Agreement [Member]
|
Jul. 31, 2013
University of Texas M.D. Anderson Cancer Center [Member]
Clinical Trial Agreement [Member]
|
Sep. 26, 2012
Johns Hopkins University [Member]
Clinical Trial Agreement [Member]
|
Sep. 30, 2014
Johns Hopkins University [Member]
Clinical Trial Agreement [Member]
|
Sep. 30, 2014
University of Pennsylvania [Member]
Clinical Trial Agreement [Member]
|
Dec. 31, 2013
University of Pennsylvania [Member]
Clinical Trial Agreement [Member]
|
Nov. 21, 2012
University of Pennsylvania [Member]
Clinical Trial Agreement [Member]
|
|
Commitments and Contingencies (Textual) | ||||||||||||||||||||||||||||||||||||||
Net sales in milestones payment | $ 10,000,000 | |||||||||||||||||||||||||||||||||||||
License fee payment | 3,000,000 | |||||||||||||||||||||||||||||||||||||
Milestones payments | 7,750,000 | 1,500,000 | 750,000 | 750,000 | 1,000,000 | |||||||||||||||||||||||||||||||||
Description of royalty payment | Company shall pay to AbbVie Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire. | Royalty payments of 2% of net sales will be due to FHCRC. | ||||||||||||||||||||||||||||||||||||
Royalty of net sales percentage | 12.00% | 2.00% | ||||||||||||||||||||||||||||||||||||
First commercial sale period | 12 years 6 months | |||||||||||||||||||||||||||||||||||||
Purchase of radioactive material used for research and development | 300,000 | 400,000 | ||||||||||||||||||||||||||||||||||||
Project estimated cost for clinical trials of drug Ac-225-HuM195 | 3,300,000 | 2,300,000 | 2,200,000 | 2,200,000 | 2,200,000 | 1,200,000 | ||||||||||||||||||||||||||||||||
Down payment of project estimated cost percentage | 12.50% | |||||||||||||||||||||||||||||||||||||
Down payment for project | 1,900,000 | 239,000 | 239,000 | |||||||||||||||||||||||||||||||||||
Clinical trial cost for approval of food and drug administration | 23,500,000 | 13,200,000 | ||||||||||||||||||||||||||||||||||||
Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years ) | 150,000 | |||||||||||||||||||||||||||||||||||||
Fund for Fred Hutchinson Cancer Research Center lab ( thereafter ) | 250,000 | |||||||||||||||||||||||||||||||||||||
Number of Patients | 24 | |||||||||||||||||||||||||||||||||||||
Amount paid to each patient after Completing clinical trial | 16,000 | 31,366 | 500,000 | 34,383 | 38,501 | 31,771 | ||||||||||||||||||||||||||||||||
Start-up fee for clinical trial | 19,749 | 33,946 | 22,847 | 16,000 | ||||||||||||||||||||||||||||||||||
Start-up due cost paid date | Dec. 31, 2013 | |||||||||||||||||||||||||||||||||||||
Non - refundable institutional fee | 562,790 | 14,500 | ||||||||||||||||||||||||||||||||||||
Annual pharmacy fee | 2,025 | |||||||||||||||||||||||||||||||||||||
Amendment processing fee | 500 | |||||||||||||||||||||||||||||||||||||
Accrued expenses | 16,000 | |||||||||||||||||||||||||||||||||||||
Accrued fees paid | 16,000 | |||||||||||||||||||||||||||||||||||||
Research recorded fees | 3,773,438 | 778,232 | 8,236,343 | 2,373,200 | 100,000 | 75,000 | 100,000 | 16,000 | ||||||||||||||||||||||||||||||
Total project estimated to cost | 800,000 | 183,391 | ||||||||||||||||||||||||||||||||||||
Research and development costs | 300,000 | 92,000 | ||||||||||||||||||||||||||||||||||||
Security deposit | $ 34,733 | $ 34,733 |